Assignee
AMGEN FREMONT INC
US·44 granted patents·9 pending applications·1,727 citations·filing 2000–2019
Top patents by PatentIndex Score
53 records- 0198US7824679B2Human monoclonal antibodies to CTLA-4AMGEN FREMONT INC·Filed 2007·Granted Nov 2, 2010·87 cites·19 claims
- 0298US7411057B2Nucleic acids encoding human monoclonal antibodies to CTLA-4AMGEN FREMONT INC·Filed 2005·Granted Aug 12, 2008·87 cites·38 claims
- 0397US8883984B2Human monoclonal antibodies to CTLA-4AMGEN FREMONT INC·Filed 2013·Granted Nov 11, 2014·38 cites·24 claims
- 0497US7807797B2Human monoclonal antibodies to CTLA-4AMGEN FREMONT INC·Filed 2007·Granted Oct 5, 2010·76 cites·25 claims
- 0597US7807798B2Human monoclonal antibodies to epidermal growth factor receptorAMGEN FREMONT INC·Filed 2005·Granted Oct 5, 2010·37 cites·11 claims
- 0697US7736644B2Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofAMGEN FREMONT INC·Filed 2004·Granted Jun 15, 2010·77 cites·115 claims
- 0797US7628986B2Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofAMGEN FREMONT INC·Filed 2004·Granted Dec 8, 2009·119 cites·83 claims
- 0897US7626012B2Nucleic acid molecules which encode antibodies that bind CD40AMGEN FREMONT INC·Filed 2008·Granted Dec 1, 2009·53 cites·21 claims
- 0997US7618633B2Antibodies that bind CD40 and methods of treating cancer and enhancing immune responsesAMGEN FREMONT INC·Filed 2007·Granted Nov 17, 2009·63 cites·45 claims
- 1097US7435871B2Transgenic animals bearing human Igλ light chain genesAMGEN FREMONT INC·Filed 2002·Granted Oct 14, 2008·173 cites·9 claims
- 1196US7566772B2Antibodies against interleukin-1βAMGEN FREMONT INC·Filed 2006·Granted Jul 28, 2009·72 cites·19 claims
- 1295US7423128B2Anti-properdin antibodies, and methods for making and using sameAMGEN FREMONT INC·Filed 2004·Granted Sep 9, 2008·82 cites·34 claims
- 1395US7285269B2Antibodies directed to tumor necrosis factorAMGEN FREMONT INC·Filed 2003·Granted Oct 23, 2007·101 cites·35 claims
- 1494US7964193B2Antibodies against interleukin-1 βAMGEN FREMONT INC·Filed 2009·Granted Jun 21, 2011·29 cites·12 claims
- 1594US7932372B2Antibodies to MAdCAMAMGEN FREMONT INC·Filed 2006·Granted Apr 26, 2011·30 cites·52 claims
- 1694US7728113B2Methods of treating arthritic conditions with antibodies to M-CSFAMGEN FREMONT INC·Filed 2007·Granted Jun 1, 2010·21 cites·27 claims
- 1793US7815907B2Antibodies to insulin-like growth factor I receptorAMGEN FREMONT INC·Filed 2005·Granted Oct 19, 2010·21 cites·97 claims
- 1893US7547817B2Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regionsAMGEN FREMONT INC·Filed 2005·Granted Jun 16, 2009·25 cites·26 claims
- 1993US7537762B2Human monoclonal antibodies to activin receptor-like kinase-1AMGEN FREMONT INC·Filed 2006·Granted May 26, 2009·34 cites·15 claims
- 2093US7498420B2Antibodies to c-MetAMGEN FREMONT INC·Filed 2004·Granted Mar 3, 2009·60 cites·34 claims
- 2193US7378091B2Antibodies against carbonic anhydrase IX (CA IX) tumor antigenAMGEN FREMONT INC·Filed 2002·Granted May 27, 2008·44 cites·25 claims
- 2293US7135174B2Antibodies directed to PDGFD and uses thereofAMGEN FREMONT INC·Filed 2002·Granted Nov 14, 2006·47 cites·4 claims
- 2392US7807159B2Antibodies to myostatinAMGEN FREMONT INC·Filed 2006·Granted Oct 5, 2010·102 cites·14 claims
- 2491US9963508B2Human monoclonal antibodies to CTLA-4AMGEN FREMONT INC·Filed 2014·Granted May 8, 2018·6 cites·13 claims
- 2590US8821869B2Treatment methods using c-Met antibodiesAMGEN FREMONT INC·Filed 2013·Granted Sep 2, 2014·13 cites·15 claims
- 2690US7579186B1Human monoclonal antibody against TGF-β type II receptor and medicinal use thereofAMGEN FREMONT INC·Filed 2000·Granted Aug 25, 2009·51 cites·29 claims
- 2790US7318925B2Methods of use for antibodies against parathyroid hormoneAMGEN FREMONT INC·Filed 2004·Granted Jan 15, 2008·30 cites·27 claims
- 2890US7288253B2Antibodies directed to parathyroid hormone (PTH) and uses thereofAMGEN FREMONT INC·Filed 2003·Granted Oct 30, 2007·32 cites·16 claims
- 2989US7982024B2Antibodies to insulin-like growth factor I receptorAMGEN FREMONT INC·Filed 2010·Granted Jul 19, 2011·11 cites·24 claims
- 3088US7867494B2Anti-IgE antibodiesAMGEN FREMONT INC·Filed 2008·Granted Jan 11, 2011·30 cites·14 claims
- 3188US7265212B2Anti-CD45RB antibodiesAMGEN FREMONT INC·Filed 2002·Granted Sep 4, 2007·33 cites·8 claims
- 3285US7572444B2Binding proteins specific for human matriptaseAMGEN FREMONT INC·Filed 2005·Granted Aug 11, 2009·12 cites·17 claims
- 3384US7993643B2Uses of human monoclonal antibodies against oxidized LDL receptorAMGEN FREMONT INC·Filed 2007·Granted Aug 9, 2011·8 cites·28 claims
- 3483US7625549B2Determining the risk of human anti-human antibodies in transgenic miceAMGEN FREMONT INC·Filed 2005·Granted Dec 1, 2009·3 cites·24 claims
- 3582US7429380B2Production of a multimeric protein by cell fusion methodAMGEN FREMONT INC·Filed 2003·Granted Sep 30, 2008·5 cites·13 claims
- 3681US11492411B2Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofAMGEN FREMONT INC·Filed 2019·Granted Nov 8, 2022·0 cites·20 claims
- 3781US7820877B2Transgenic mammals having human IG loci including plural Vh and Vk regions and antibodies produced therefromAMGEN FREMONT INC·Filed 2005·Granted Oct 26, 2010·3 cites·10 claims
- 3881US7771951B2Antibody categorization based on binding characteristicsAMGEN FREMONT INC·Filed 2002·Granted Aug 10, 2010·5 cites·52 claims
- 3979US10280219B2Antibodies to M-CSFAMGEN FREMONT INC·Filed 2017·Granted May 7, 2019·1 cites·12 claims
- 4078USRE45847EAntibodies to MAdCAMAMGEN FREMONT INC·Filed 2014·Granted Jan 19, 2016·2 cites·52 claims
- 4175US10508153B2Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereofAMGEN FREMONT INC·Filed 2015·Granted Dec 17, 2019·1 cites·61 claims
- 4270US2010098694A1Antibodies to cd40AMGEN FREMONT INC·Filed 2009·Application pending·0 cites
- 4369US2019202905A1Antibodies to m-csfAMGEN FREMONT INC·Filed 2019·Application pending·0 cites
- 4465US9234041B2Antibodies to insulin-like growth factor I receptorAMGEN FREMONT INC·Filed 2013·Granted Jan 12, 2016·0 cites·20 claims
- 4562US9718883B2Antibodies to M-CSFAMGEN FREMONT INC·Filed 2015·Granted Aug 1, 2017·0 cites·39 claims
- 4662US2013344514A1Reducing the risk of human anti-human antibodies through v gene manipulationAMGEN FREMONT INC·Filed 2013·Application pending·0 cites
- 4761US7754433B2Identification of high affinity molecules by limited dilution screeningAMGEN FREMONT INC·Filed 2002·Granted Jul 13, 2010·3 cites·20 claims
- 4861US2015250152A1Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefromAMGEN FREMONT INC·Filed 2014·Application pending·0 cites
- 4959US2016152713A1Antibodies to cd40AMGEN FREMONT INC·Filed 2015·Application pending·0 cites
- 5052US2014105905A1High Affinity Fully Human Monoclonal Antibodies To Interleukin-8 And Epitopes For Such AntibodiesAMGEN FREMONT INC·Filed 2013·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when AMGEN FREMONT INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →